---
created: 2025-04-13
updated: 2025-04-13T10:53
id: KkWC#LT,O^
specialty: pharmaco
specialty_id: 453
tags:
  - source/ak-original-decks::step-1::lolnotacop::drugs
  - "source/ak-step1-v11:": 
  - theme/b&b::11-hematology::04-cancer-drugs::01-antimetabolites
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::12-antimetabolites
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::12-antimetabolites::pyrimidine-synthesis-inhibitors::*basics
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::11-oncology::hydroxyurea
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::01-antimetabolites::01-methotrexate,-leucovorin,-5-fluorouracil,-hydroxyurea
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::19000-19999::19689"
type: flashcard
---

# Question
Thymidine synthesis inhibitor (MTX, 5-FU, hydroxyurea) use can result in **myelo**-suppression and **pan**-cytopenia

---

# Answer
Inhibition of a nucleic acid synthesis enzyme  hydroxyurea inhibits ribonucleoside reductase, an enzyme that generates deoxyribonucleoside triphosphates for DNA synthesis/repair == macrocytosis and, in high doses, pancytopenia